ASP Isotopes Inc. (NASDAQ:ASPI) Shares Acquired by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD lifted its position in shares of ASP Isotopes Inc. (NASDAQ:ASPI) by 14.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,646 shares of the company’s stock after purchasing an additional 2,757 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in ASP Isotopes were worth $99,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ASPI. Hanson & Doremus Investment Management purchased a new position in shares of ASP Isotopes during the 4th quarter valued at approximately $27,000. Avantax Advisory Services Inc. purchased a new position in shares of ASP Isotopes during the 4th quarter valued at approximately $45,000. Russell Investments Group Ltd. lifted its position in shares of ASP Isotopes by 56.3% during the 4th quarter. Russell Investments Group Ltd. now owns 10,221 shares of the company’s stock valued at $46,000 after buying an additional 3,682 shares in the last quarter. SVB Wealth LLC purchased a new position in shares of ASP Isotopes during the 4th quarter valued at approximately $49,000. Finally, Boston Financial Mangement LLC purchased a new position in shares of ASP Isotopes during the 4th quarter valued at approximately $50,000. Hedge funds and other institutional investors own 16.80% of the company’s stock.

ASP Isotopes Trading Up 14.6%

Shares of ASPI stock opened at $7.29 on Monday. The stock’s fifty day moving average is $5.21 and its two-hundred day moving average is $5.43. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.54 and a current ratio of 7.55. The firm has a market capitalization of $547.20 million, a P/E ratio of -11.95 and a beta of 3.40. ASP Isotopes Inc. has a fifty-two week low of $1.86 and a fifty-two week high of $9.33.

Insiders Place Their Bets

In other ASP Isotopes news, CEO Paul Elliot Mann sold 316,666 shares of the firm’s stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $5.62, for a total value of $1,779,662.92. Following the completion of the sale, the chief executive officer now directly owns 7,315,454 shares of the company’s stock, valued at $41,112,851.48. This trade represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Robert Ainscow sold 66,666 shares of the firm’s stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $5.75, for a total value of $383,329.50. Following the completion of the sale, the chief operating officer now directly owns 1,553,326 shares of the company’s stock, valued at $8,931,624.50. This trade represents a 4.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 766,667 shares of company stock valued at $4,358,502 in the last three months. 21.40% of the stock is currently owned by insiders.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.